price
RV
NASDAQ · RVMD
Revolution Medicines, Inc.
Healthcare · Biotechnology
$204.86
Down-$0.25 (-0.12%)
Updated Sep 16, 2026, 7:37 AM
SID Score
7.2/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 15.18B
- P/E ratio
- -15.46
- Dividend yield
- 0.00%
- 52-week range
- $42.18 – $224.31
- Volume
- 1.27M
- Avg. volume
- 2.27M
Price performance
RVMD price history
1M range · 20 trading sessions · Daily adjusted prices
RVMD closed at $204.86 after 20 trading sessions, down 5.16% for the selected period.
- Last close
- $204.86
- Period change
- -5.16%
- Period low
- $203.35
- Period high
- $221.15
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $206.98 | $207.00 | $200.24 | $204.86 | 1.27M |
| Sep 14, 2026 | $203.50 | $206.55 | $200.17 | $205.11 | 1.27M |
| Sep 11, 2026 | $204.98 | $206.36 | $197.8125 | $203.77 | 1.38M |
| Sep 10, 2026 | $205.85 | $207.84 | $202.5901 | $203.35 | 810.66K |
| Sep 9, 2026 | $206.01 | $213.00 | $204.46 | $207.68 | 1.23M |
| Sep 8, 2026 | $208.07 | $213.00 | $206.30 | $207.32 | 2.39M |
| Sep 4, 2026 | $209.01 | $211.75 | $207.48 | $210.02 | 885.06K |
| Sep 3, 2026 | $207.04 | $212.06 | $207.04 | $210.87 | 1.12M |
| Sep 2, 2026 | $211.36 | $211.9099 | $205.22 | $209.23 | 1.33M |
| Sep 1, 2026 | $204.64 | $210.255 | $202.54 | $209.87 | 1.83M |
| Aug 31, 2026 | $205.14 | $207.02 | $200.5301 | $205.57 | 2.27M |
| Aug 28, 2026 | $221.50 | $221.50 | $205.82 | $207.88 | 2.01M |
| Aug 27, 2026 | $219.48 | $224.31 | $216.13 | $221.15 | 3.36M |
| Aug 26, 2026 | $209.32 | $218.30 | $198.9144 | $215.44 | 3.52M |
| Aug 25, 2026 | $214.27 | $216.24 | $209.63 | $211.38 | 1.38M |
| Aug 24, 2026 | $209.46 | $211.95 | $205.39 | $211.58 | 1.6M |
| Aug 21, 2026 | $212.06 | $212.74 | $206.75 | $209.46 | 2.12M |
| Aug 20, 2026 | $212.26 | $213.7381 | $208.02 | $211.735 | 1.56M |
| Aug 19, 2026 | $218.84 | $220.34 | $212.25 | $214.66 | 1.31M |
| Aug 18, 2026 | $209.15 | $216.72 | $209.09 | $216.00 | 1.65M |
Latest RVMD news
The latest Smart Investors Daily articles mentioning RVMD.
Stock researchCompany · Overview
RVMD research
Overview
Company profile and research snapshot.
Company profile
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $82.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | Morgan Stanley | Overweight | — |
| Sep 9, 2026 | Stifel | Buy | — |
| Aug 31, 2026 | Needham | Buy | — |
| Aug 28, 2026 | UBS | Buy | — |
| Aug 28, 2026 | Guggenheim | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.